Sionna Therapeutics (NASDAQ:SION) Stock Rating Lowered by JonesTrading

Sionna Therapeutics (NASDAQ:SION) was downgraded by investment analysts at JonesTrading from a “strong-buy” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

A number of other brokerages have also recently issued reports on SION. Wedbush cut Sionna Therapeutics from an “outperform” rating to a “neutral” rating and set a $5.00 target price for the company. in a research report on Monday. Guggenheim cut Sionna Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday. Wall Street Zen downgraded Sionna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Citigroup lowered shares of Sionna Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday. Finally, BTIG Research cut shares of Sionna Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday. One analyst has rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $42.22.

Sionna Therapeutics Stock Up 13.3%

SION stock opened at $5.10 on Monday. The business has a 50 day moving average price of $40.99 and a 200 day moving average price of $39.92. The stock has a market cap of $230.58 million, a price-to-earnings ratio of -2.34 and a beta of 1.32. Sionna Therapeutics has a fifty-two week low of $4.01 and a fifty-two week high of $54.97.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.02). As a group, sell-side analysts anticipate that Sionna Therapeutics will post -2.66 EPS for the current year.

Insider Activity

In other news, Director Peter A. Thompson sold 115,844 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total transaction of $5,270,902.00. Following the sale, the director owned 2,555,877 shares of the company’s stock, valued at $116,292,403.50. The trade was a 4.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 115,844 shares of the firm’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $45.50, for a total value of $5,270,902.00. Following the completion of the transaction, the director owned 2,555,877 shares of the company’s stock, valued at approximately $116,292,403.50. This represents a 4.34% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 403,726 shares of company stock worth $18,259,354 over the last 90 days. 5.10% of the stock is currently owned by company insiders.

Institutional Trading of Sionna Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in SION. Russell Investments Group Ltd. purchased a new stake in Sionna Therapeutics in the 3rd quarter worth approximately $30,000. BNP Paribas Financial Markets acquired a new stake in Sionna Therapeutics during the 2nd quarter valued at approximately $31,000. State of Wyoming purchased a new stake in Sionna Therapeutics during the 2nd quarter worth approximately $35,000. GF Fund Management CO. LTD. acquired a new position in shares of Sionna Therapeutics in the 4th quarter valued at approximately $36,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Sionna Therapeutics during the 2nd quarter valued at approximately $44,000.

More Sionna Therapeutics News

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: Royal Bank of Canada upgraded Sionna Therapeutics from “underperform” to “sector perform,” while Stifel Nicolaus maintained a “hold” rating with a $7 price target. These actions suggest some analysts believe the post-trial selloff may have been excessive. Royal Bank of Canada upgrade
• Neutral Sentiment: Several firms moved to more cautious but non-bearish ratings, including “neutral,” “market perform,” “sector perform,” or “hold” from Wedbush, Guggenheim, Raymond James, BTIG, Lifesci Capital, JonesTrading, and Stifel. The broad analyst reset reflects substantially reduced expectations following the clinical setback. Analyst rating changes
• Negative Sentiment: Sionna reported that its lead candidate, SION-719, failed to meet the key endpoint in a Phase 2 cystic fibrosis trial. The company discontinued development of the drug as an add-on therapy, removing what had been its principal near-term opportunity to challenge Vertex Pharmaceuticals’ dominant CF franchise. Sionna halts SION-719
• Negative Sentiment: The trial failure has sharply damaged Sionna’s investment thesis, with reports describing the shares as down more than 90% and at a record or 12-month low. Investors are reassessing the company’s remaining pipeline, funding needs, and ability to create value without its lead program. Sionna trial failure and share decline
• Negative Sentiment: The concentrated analyst downgrades reinforce the bearish reaction: BTIG and Guggenheim shifted from buy ratings to neutral, while Raymond James, Wedbush, Lifesci Capital, and JonesTrading also reduced their recommendations. Wedbush and RBC both cited approximately $5 price targets, leaving limited near-term upside at the reported price. Sionna analyst downgrades

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.